Replimune Group, Inc. reported significant financial results for the three and nine months ended December 31, 2025, revealing a net loss of $70.9 million for the quarter, compared to a loss of $66.3 million in the same period of 2024. For the nine-month period, the company recorded a net loss of $240.7 million, up from $173.2 million year-over-year. The increase in losses is attributed primarily to heightened research and development expenses, which rose to $53.1 million for the quarter and $168.9 million for the nine months, reflecting ongoing clinical trials and operational costs associated with their proprietary RPx platform.
The company’s total operating expenses for the three months ended December 31, 2025, were $71.9 million, compared to $66.0 million in the prior year. This increase was driven by a $5.1 million rise in research and development costs, particularly related to the RP1 program, which is currently undergoing multiple clinical trials. Selling, general, and administrative expenses also saw an increase, totaling $18.7 million for the quarter, up from $18.0 million in the previous year, as the company prepares for potential commercialization of its product candidates.
In terms of strategic developments, Replimune has made progress with its lead product candidate, RP1, which is under review by the FDA following a resubmission of its Biologics License Application (BLA) after receiving a complete response letter in July 2025. The FDA has set a new PDUFA date of April 10, 2026, for the resubmitted application. The company is also advancing its clinical trials, including the IGNYTE-3 trial, which aims to assess RP1 in combination with nivolumab in patients with advanced melanoma who have failed prior treatments.
Operationally, Replimune reported cash and cash equivalents of $122.9 million as of December 31, 2025, down from $111.1 million at the end of the previous quarter. The company’s total assets decreased to $333.6 million from $551.3 million, primarily due to a reduction in short-term investments. The company anticipates that its existing cash and cash equivalents, along with potential additional funding from its loan agreement with Hercules Capital, will be sufficient to support operations through at least the first quarter of 2027.
Looking ahead, Replimune expects to continue incurring significant losses as it advances its clinical programs and prepares for potential commercialization of RP1. The company remains focused on securing regulatory approvals and establishing a market presence for its product candidates, while also navigating the complexities of the biotechnology landscape, including competition and regulatory challenges.
About Replimune Group, Inc.
Replimune Group, Inc. is a biotechnology company specializing in oncolytic immunotherapy for cancer treatment. Its proprietary RPx platform uses engineered herpes simplex virus to activate immune responses against tumors, aiming to improve efficacy and safety. The company develops virus-based therapies, including RP1, RP2, and RP3, targeting skin cancers, melanoma, and other tumor types, often in combination with immune checkpoint inhibitors, to enhance anti-tumor immunity.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.